Genentech's Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD [Yahoo! Finance]
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
Healthy diets spark lung cancer risk in non-smokers as pesticides loom [FOX News]
FDA Accepts Application for Genentech's Gazyva for the Treatment of the Most Common Form of Lupus [Yahoo! Finance]
FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus